Cormorant Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Cormorant Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-200,000	Closed	-$30.6M	–	121
2020 Q4	$30.6M	Sell	200,000 -100,000	-33%	-$11.8M	0.73%	37
2020 Q3	$25.1M	Sell	300,000 -100,000	-25%	-$8.87M	0.96%	34
2020 Q2	$29.4M	Sell	400,000 -230,400	-37%	-$13.5M	1.12%	28
2020 Q1	$26.7M	Sell	630,400 -369,600	-37%	-$19.1M	1.24%	26
2019 Q4	$60.9M	Sell	1,000,000 -84,300	-8%	-$4.6M	2.43%	11
2019 Q3	$44.4M	Buy	1,084,300 +384,300	+55%	+$18.4M	2.71%	9
2019 Q2	$33M	Sell	700,000 -200,000	-22%	-$7.99M	1.89%	18
2019 Q1	$32.1M	Buy	900,000 +800,000	+800%	+$27.7M	2.17%	17
2018 Q4	$2.86M	Buy	+100,000	New	+$3.48M	0.23%	60

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Cormorant Asset Management's CRSP Position: Q1 2021 in Review

Cormorant Asset Management sold out of CRISPR Therapeutics (CRSP) in Q1 2021, closing a stake of 200,000 shares — an estimated $30.6M sold.

Cormorant Asset Management first reported a position in CRSP in Q4 2018 and held it in 9 quarters. The position peaked at $60.9M in Q4 2019. 443 funds tracked by Wall St. Rank hold CRSP as of Q1 2021.

Cormorant Asset Management reported no remaining CRISPR Therapeutics position as of Q1 2021 after selling out during the quarter.
Cormorant Asset Management sold 200,000 CRISPR Therapeutics shares in Q1 2021, an estimated $30.6M.
Cormorant Asset Management first reported a position in CRISPR Therapeutics in Q4 2018 and held it in 9 quarters.
Cormorant Asset Management's CRISPR Therapeutics position peaked at $60.9M in Q4 2019.
443 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2021.

Based on Cormorant Asset Management's 13F filing for Q1 2021, filed 17 May 2021.